Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Xeris Biopharma Holdings, Inc.

Get SEC filing alerts via email and in your feed for Xeris Biopharma Holdings, Inc.

XERS

Xeris Biopharma Holdings, Inc.

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings develops and commercializes therapies for chronic endocrine and neurological diseases. Its core products include Recorlev for Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. The company leverages proprietary formulation technologies (XeriSol and XeriJect) to create stable, ready-to-use injectable drugs and partners with other biopharmaceutical firms to expand its pipeline and delivery options.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Xeris Biopharma Holdings, Inc.

1
1
Xeris Biopharma Holdings, Inc. Xeris Biopharma Reports 43.6% Revenue Growth to $291.8 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
Xeris Biopharma Holdings, Inc. Xeris Biopharma Reports Revenue Growth, Increased Losses, and Strategic Developments in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments